Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule.

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Nov 24, 2022

Keywords

ClinConnect Summary

Management of the neck in Wang cT1-T2N0 nasal vestibule carcinoma (NVC) has been an ongoing point of discussion. As the disease is rare publications are scarce and published regional recurrence rates vary widely between 0% up to 23%. In general, literature recommends adequate radiological neck staging followed by a watchful waiting policy, as overall regional recurrence rates are low (5-10%).

However, according to recent findings, a subset of patients with large or voluminous cT1-T2N0 NVC is deemed at high risk of nodal involvement (20-40% regional recurrence) but receive no elective treat...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or older.
• • WHO performance score of 0, 1 or 2.
• • Newly diagnosed T1 or T2 squamous cell carcinoma of the nasal vestibule.
• • Tumor diameter ≥1.5 cm and/or tumor volume ≥1.5cm3
• • Clinically negative neck (N0).
• • Patients planned to undergo curative treatment.
• • Patient provided written informed consent
• Exclusion Criteria:
• • Prior allergic reaction to either indocyanide green, 99m-Technetium nanocolloid or human colloidal albumin.
• • Pregnancy.
• • Previous surgery or radiotherapy of the neck.
• • Concurrent secondary head-and-neck tumor.
• • Unable to provide informed consent

Trial Officials